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ABSTRACT
Objective: to evaluate the main clinical symptoms associated with the toxic effects of antineoplastic ther-
apy in women with breast cancer at a cancer treatment center in the city of Caruaru/PE. 
Methods: This is an analytical and transversal study with a quantitative approach, carried out between 
September and December 2017, whose data source was the medical records of the patients included in 
the study. 
Results: the majority of the sample consisted of women aged between 41 and 50 years (28.6%). This 
study made it possible to identify the most frequent histological type of breast cancer, with invasive 
ductal carcinoma observed in 88.6% and the most used protocol was Doxorubicin, Cyclophosphamide 
and Paclitaxel. Alopecia (91.4%) was the main adverse event observed in patients. 
Conclusion: it was possible to verify that the observation of these effects, allows a better control during 
the therapy, enabling improvement of the time and quality of life.
Keywords: Antineoplastic Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; 
Cancer; Medical oncology. 
RESUMEN
Objetivo: evaluar los principales síntomas clínicos asociados con los efectos tóxicos de la terapia an-
tineoplásica en mujeres con cáncer de mama en un centro de tratamiento del cáncer en la ciudad de 
Caruaru/PE. 
Métodos: este es un estudio analítico y transversal con un enfoque cuantitativo, realizado entre septiem-
bre y diciembre de 2017, cuya fuente de datos fueron las historias clínicas de los pacientes incluidos en 
el estudio.
Resultados: la mayor parte de la muestra estuvo formada por mujeres de 41 a 50 años (28,6%). Este es-
tudio permitió identificar el tipo histológico más frecuente de cáncer de mama, con un carcinoma ductal 
invasivo observado en el 88,6% y el protocolo más utilizado fue la doxorubicina, la ciclofosfamida y el 
paclitaxel. La alopecia (91,4%) fue el principal evento adverso observado en los pacientes.
Conclusión: fue posible verificar que la observación de estos efectos permite un mejor control durante la 
terapia, lo que permite mejorar el tiempo y la calidad de la vida.
Palabras clave: Antineoplásicos; Neoplasias de la Mama; Efectos Colaterales y Reacciones Adversas Re-
lacionados con Medicamentos; Oncología Médica.
Artículo Original 
Original Article
Correspondencia 
Correspondence
Iago Dillion Lima Cavalcanti,
Specialist in Cancer Attention and 
Palliative Care, University Center Tabosa 
of Almeida - ASCES/UNITA, Caruaru, 
Pernambuco, Brazil 
e-mail: iagodillion@hotmail.com
Financiación 
Fundings
No fundings received
Conflicto de interés 
Competing interest
None daclared
Received: 02.11.2018 
Accepted: 27.11.2018
Toxic effects of antineoplastic therapy in patients breast cancer in 
Caruaru-PE oncology center
Efectos tóxicos de la terapia antineoplásica en pacientes cáncer de mama en el cen-
tro de oncología Caruaru-PE
Rayssa Almeida Carneiro1, Ana Caroline de Brito França1, Sabryna Aleadynah Barbosa da Silva1, Iago Dillion 
Lima Cavalcanti1, Analúcia Guedes Silveira Cabral1 and Adrya Lucia Peres1
1 University Center Tabosa of Almeida – ASCES/UNITA, Caruaru, Pernambuco, Brazil
http://dx.doi.org/10.30827/ars.v59i4.8113
222 Ars Pharm. 2018; 59(4): 221-226
Almeida Carneiro R, et al.
INTRODUCTION
Breast cancer is the most common among women in the 
world and in Brazil, accounting for about 25% of new cases 
per year, the estimated number of new cases for the year 
2016 is 57,960. Breast cancer may also be present in men; 
however, it is very rare, accounting for only 1% of the total 
cases of the disease. Relatively rare before age 35, breast 
cancer increases its incidence proportionally with advanc-
ing age, especially after age 50(1).
Mammary neoplasia is a pathology feared today, especially 
by women. It is commonly associated with physical muti-
lation, changes in style and quality of life, and despite the 
technological advancement in health in relation to treat-
ment and the increase in mass-mediated information, neo-
plasia rates are high worldwide, in the that it is Brazil gen-
erally the disease is diagnosed in advanced stages, making 
treatment difficult(2).
When breast cancer is diagnosed, the patient will undergo 
a combination of treatments, including surgery, radiation 
therapy, chemotherapy and hormone therapy, as well as 
possible unconventional treatments for her physical and 
mental well-being(3).
The main goal of antineoplastic chemotherapy is to destroy 
the cancer cells while preserving the normal ones. How-
ever, many chemotherapeutic agents act in a non-specific 
way, damaging both malignant and normal cells of rapid 
division, such as gastrointestinal, capillary and immune 
systems, leading to side effects of chemotherapy such as: 
nausea, hair loss and greater susceptibility infections. In 
addition, the fact that the biochemical and morphological 
differences of normal and malignant cells are minimal there 
is a difficulty in the immune response on top of these cells 
and this facilitates their growth so that they develop resist-
ance to antineoplastics rapidly(4).
The antineoplastic agents most employed in the treatment 
of cancer include polyfunctional alkylants, antimetabo-
lites, antitumor antibiotics, mitotic inhibitors and the like. 
New drugs are being permanently isolated and applied 
experimentally in animal models before they are used in 
humans(5).
A better knowledge of the adverse effects in response to dif-
ferent protocols commonly used in antineoplastic therapy 
of breast cancer will allow a better definition of the main 
effects presented, thus allowing the development of strate-
gies and behaviors that minimize these effects, improving 
the patient quality of life. The objective of this study was 
to evaluate the main clinical symptoms associated with the 
toxic effects of antineoplastic therapy in women with breast 
cancer at a cancer treatment center in the city of Caruaru/
PE.
METHODS
This is an analytical and cross-sectional quantitative study, 
carried out between September and December 2017 in an 
oncology center, located in the city of Caruaru/PE. Data 
collection was performed through a questionnaire with the 
following variables: age, tumor histological type, chemo-
therapy protocol and cycle. The undesirable effects present-
ed by the patients during the chemotherapy treatment were 
also identified through the analysis of the medical records 
and the patient reports.
Included in the study were all women diagnosed with 
breast cancer treated during the study period who were 
older than 20 years and who were taking antineoplastic 
therapy. On the other hand, women who underwent radia-
tion therapy and patients who abandoned chemotherapeu-
tic treatment were excluded.
The information obtained through the data collection was 
organized and analyzed through descriptive statistical 
techniques through absolute distributions, percentage of 
measures and techniques of inferential statistics. The soft-
ware used was EpiData and Microsolft® Office Excel 2013.
Ethical approval
All procedures performed in studies involving human par-
ticipants were performed under an approved protocol and 
in accordance with the ethical standards of the Institutional 
Research Committee of Caruaruense Association of Higher 
Education and Technical (Approval No. 2.158.459) and with 
the 1964 Helsinki Declaration and its later amendments or 
comparable ethical standards.
RESULTS
The study consisted of 35 female patients on antineoplas-
tic chemotherapy. According to table 1, the age group with 
the highest number of patients was 41-50 years (28.6%), fol-
lowed by patients aged between 51 and 60 years (22.9%). 
In the histological classification of cancer, we highlight the 
invasive ductal carcinoma, 31 women (88.6%), followed by 
lobular carcinoma, three women (8.6%) and lastly other 
types of cancer, one woman (2.9%). It was also verified that 
about 23% of the patients had hypertension and 8.6% had 
diabetes.
As shown in Figure 1, the protocols most used by the study 
patients were as follows: Doxorubicin, Cyclophosphamide 
and Paclitaxel (28.57%), Paclitaxel (11.42%), Anastrozole 
and Paclitaxel and Carboplatin (8.57%).
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Table 1: Absolute and relative frequency of patients diagnosed 
with breast cancer at a cancer treatment center by age group (in 
years), histological type of cancer and chronic diseases. Caruaru, 
Pernambuco, Brazil, 2017, (n = 35).
n (absolute 
frequency)
% (relative 
frequency)
Age group (years)
20 - 30 1 2.9
31 – 40 7 20.0
41 – 50 10 28.6
51 – 60 8 22.9
61 – 70 6 17.1
80 years or more 3 8.6
Histological Type
Invasive Ductal Carci-
noma
31 88.6
Carcinoma Lobular 3 8.6
Others 1 2.9
Comorbidities
Arterial hypertension 8 22.9
Diabetes 3 8.6
Source: Research data
Figure 1: Relative frequency of protocols used by patients under-
going chemotherapy. Caruaru, Pernambuco, Brazil, 2017 (n= 35).
The main adverse events observed in the patients during 
chemotherapy were alopecia (91.4%), nausea (85.7%) and 
vomiting (68.6%), as observed in Table 2.
Table 3 shows the association of the protocols most used by 
the patients and the adverse events presented by them dur-
ing the study period. It was observed that 29.6% of the pa-
tients who used the protocol Doxorubicin, Cyclophospha-
mide and Paclitaxel (AC-T) presented alopecia, in contrast 
to the patients using the protocols with Paclitaxel (Tx) and 
Paclitaxel + Carboplatin (Tx + CBP), only 17.4% and 14.3%, 
respectively, presented with alopecia.
Table 2: Absolute and relative frequency of adverse events pre-
sented by patients undergoing chemotherapy. Caruaru, Pernam-
buco, Brazil, 2017 (n = 35).
Adverse event
n (absolute 
frequency)
% (relative 
frequency)
Taste change 18 51.4
Alopecia 32 91.4
Nauseas 30 85.7
Vomiting 24 68.6
Decreased appetite 15 42.9
Dizziness 10 28.6
Physical tiredness 23 65.7
Somnolence 10 28.6
Source: Research data
Table 3: Absolute and relative frequency of association of 
protocols and adverse events presented by patients diagnosed 
with breast cancer in an antineoplastic treatment clinic. Caruaru, 
Pernambuco, Brazil, 2017.
AC-T Paclitaxel Tx+CBP
Taste change 2 (7.4%) 2 (7.4%) 3 (10.7%)
Alopecia 8 (29.6%) 3 (13%) 4 (14.3%)
Nauseas 5 (18.5%) 4 (14.3%)  4 (14.3%)
Vomiting 5 (18.5%) 2 (7.4%) 4 (14.3%)
Decreased 
appetite
2 (7.4%) 1 (4.3%) 4 (14.3%)
Dizziness - 1 (4,3%) 3 (10.7%)
Physical 
tiredness
4 (14.3%) 3 (13%) 4 (14.3%)
Somnolence 1 (3.7%) 2 (8.7%) 2 (7.1%)
Legend: AC-T: Doxorubicin, Cyclophosphamide and Paclitaxel; 
Tx: Paclitaxel; Tx+CBP: Paclitaxel and Carboplatin.
Source: Research data.
During the research, alopecia was the most frequent ab-
solute and relative adverse event in all cycles studied, as 
shown in table 4.
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Table 4: Association of Time (Cycle) with the adverse events presented by the patients diagnosed with breast cancer and in antineoplas-
tic treatment. Caruaru, Pernambuco, Brazil, 2017.
Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Cycle 7 Cycle 8 Cycle 11
Taste change 5 (27.7%) 3 (16.7%)
1 
(5.6%)
1 
(5.6%)
5 (27.7%) 1 (5.6%) 2 (11.1%) -
Alopecia 5 (15.6%) 10 (31.25%) 4 (12.5%) 2 (6.25%) 6 (18.75%) 1 (3.12%) 3 (9.37%) 1 (3.12%)
Nauseas 5 (16.67%)
9 
(30%)
4 (13.33%) 1 (3.33%)
6 
(20%)
1 
(3.33%)
3 
(10%)
1 
(3.33%)
Vomiting 2 (8.33%) 10 (41.67%) 4 (16.67%) 1 (4.17%) 3 (12.5%) 1 (4.17%) 2 (8.33%) 1 (4.17%)
Decreased ap-
petite
2 (13.33%) 4 (26.67%) 1 (6.67%) 2 (13.33%)
3 
(20%)
- 2 (13.33%) 1 (13.33%)
Dizziness -
4 
(40%)
1 
(10%)
1 
(10%)
2 
(20%)
-
2 
(20%)
-
Physical tired-
ness
3 (13.04%) 8 (34.78%) 2 (8.69%) 1 (4.35%) 5 (21.74%) - 3 (13.04%) 1 (4.35%)
Somnolence -
2 
(20%)
1 
(10%)
1 
(10%)
5 
(50%)
-
1 
(10%)
-
Source: Research data
DISCUSSION
In this study, it was possible to observe that the age group 
from 41 to 50 years (28.6%) was the most incident, which 
confirms with another study carried out in the city of 
Ribeirão Preto, located in the state of São Paulo, where there 
was a predominance of age between 41-50 years (40.9%)(6).
The most common histological type was Invasive Ductal 
Carcinoma (88.6%), presenting similarity to a retrospec-
tive epidemiological and descriptive study conducted at 
the Crato Specialty Center, Ceará (77%)(7). Another study 
conducted between 2000 and 2009 observed that the most 
frequent tumor histology among the included patients was 
the Invasive Ductal Carcinoma with 90.7%(8).
A survey of 285 individuals diagnosed with some form of 
cancer concluded that 45% of the patients were hyperten-
sive and 14.03% declared themselves diabetic. This result 
is in agreement with what was found in this study, since 
the prevalence of systemic arterial hypertension (23%) was 
higher than that of diabetes mellitus (8.6%). It is important 
to highlight that these chronic diseases have negatively 
interfered in the quality of life of individuals affected by 
these diseases, as well as their great economic impact to the 
Unified Health System (SUS), considering the high sums 
allocated for prevention, health promotion, to the treat-
ment and recovery of these pathologies and their compli-
cations(9).
The AC-T protocol (Doxorubicin, Cyclophosphamide and 
Paclitaxel) was the most used among the patients during 
the study period. The same result was obtained in the re-
search carried out in a general, university and public hos-
pital, in the hematology-oncology outpatient clinic, located 
in the State of Paraná, whose hospital attendance is solely 
by SUS(10).
Chemotherapy brings with it several commonly expected 
adverse effects during treatment, such as: nausea, vomiting, 
diarrhea or constipation, alopecia, among others. It is nec-
essary to evaluate the cost-benefit of each treatment, since 
the answers are individualized and requires a timely and 
effective intervention to minimize them(11). Among these 
adverse events, alopecia (91.4%), nausea (85.7%), vomiting 
(68.6%) and physical fatigue (65.7%) were the ones with the 
highest rates in this study.
A total of 91.4% of the women had alopecia, which is de-
fined as the loss of hair and any other body hair such as the 
eyebrows, the axillary, pubic hair and/or the legs and arms. 
This side effect occurs after one to two weeks of the onset 
of chemotherapy and is due to the lack of hair production 
or thinning caused by the abrupt interruption of the mitotic 
activity of the capillary matrix, which leads to the weaken-
ing of the capillary shaft causing the hair to fall during the 
act of combing, hair washing or even handling. Hair loss 
becomes more pronounced about one to two months after 
starting chemotherapy and, with repeated cycles of it, can 
lead to total alopecia(12).
Among the gastrointestinal adverse events we may men-
tion nausea, vomiting, mucositis, diarrhea, anorexia, sto-
matitis, discomfort or abdominal pain, but those referred 
225Ars Pharm. 2018; 59(4): 221-226
Toxic effects of antineoplastic therapy in patients breast cancer in Caruaru-PE oncology center
by cancer patients as the most stressful and uncomfortable 
are nausea and vomiting. They occur together or isolated, 
however they must be evaluated separately, because they 
are distinct events, with also different causes. In a study of 
79 women aged 29 to 69 years, 93% had nausea and 87% 
had vomiting(13).
The literature draws attention to the fatigue symptom, since 
it can directly interfere with women’s emotional well-being 
and quality of life. The caveat is for health care profession-
als who must be prepared and alert to guide patients by 
helping them recognize fatigue and clarifying appropriate 
ways to relieve this symptom(11).
The greatest benefits of chemotherapy came when the 
drugs were combined into regimens, the most common of 
which include a drug of each class example: adriamycin, 
cyclophosphamide (AC); 5-fluorouracil, adriamycin, cyclo-
phosphamide (FAC); 5-fluorouracil, epirubicin, cyclophos-
phamide (FEC); adriamycin, cyclophosphamide, paclitaxel 
(ACT), among others. Unfortunately, the adverse effects of 
these therapies have become another major problem within 
oncology and public health. Cardiovascular comorbidities, 
the risk of onset of another tumor induced by the treatment, 
pulmonary alterations, fatigue and excessive and persistent 
pains, asthenia, depression, anxiety, are symptoms com-
monly reported by people undergoing chemotherapy. Indi-
vidual tolerance to these effects has been the limiting factor 
in the use of chemotherapy doses(14).
Sanches et al(15) demonstrated a significant incidence of 
alopecia in combination regimens, such as: 50-100% with 
carboplatin, paclitaxel and 90% with cisplatin, etoposide 15. 
In view of this research, it can be seen that the incidence of 
this cutaneous reaction is higher in the protocol Carbopla-
tin and Paclitaxel, confirming with the data of our study.
It is important to emphasize that breast cancer is a public 
health problem in Brazil, because it is a disease of high fre-
quency among women and has numerous adverse effects 
during drug therapy. In view of this study, it was possible 
to verify that alopecia presents as the most frequent ad-
verse effect during oncologic chemotherapy, where the pro-
tocol combined with Carboplatin and Paclitaxel expressed 
this effect in greater proportion. Symptoms such as nausea, 
vomiting and physical tiredness are common among the 
patients studied, considering the different protocols and 
time of therapy.
The observation of these effects during the treatment, al-
lows a better control during the chemotherapy, enabling 
improvement of the time and quality of life. New studies, 
including new protocols should be performed, seeking to 
observe the various toxic effects of therapy. In this way, 
it will be possible to better care for women’s health and a 
qualified and humanized care.
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